Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia

Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib

(2010) Brady Stein et al.   CLINICAL THERAPEUTICS

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a ‘head-to-head comparison’

(2010) Gianantonio Rosti et al.   LEUKEMIA & LYMPHOMA

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients

(2009) Eric Q. Wu et al.   CURRENT MEDICAL RESEARCH AND OPINION

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?

(2009) Elias Jabbour et al.   MAYO CLINIC PROCEEDINGS

Prospective Validation of Eight Different Adherence Measures for Use with Administrative Claims Data among Patients with Schizophrenia

(2009) Sudeep Karve et al.   VALUE IN HEALTH

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

(2008) E. Jabbour et al.   BLOOD

Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis

(2008) Neil P. Shah et al.   CANCER CELL

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Milestones and Monitoring in Patients with CML Treated with Imatinib

(2008) M. W. Deininger   Hematology-American Society of Hematology Education Program